PT3801536T - Administração de sepiapterina sem alimentos para utilização num método para aumentar a exposição plasmática a sepiapterina - Google Patents

Administração de sepiapterina sem alimentos para utilização num método para aumentar a exposição plasmática a sepiapterina

Info

Publication number
PT3801536T
PT3801536T PT198118887T PT19811888T PT3801536T PT 3801536 T PT3801536 T PT 3801536T PT 198118887 T PT198118887 T PT 198118887T PT 19811888 T PT19811888 T PT 19811888T PT 3801536 T PT3801536 T PT 3801536T
Authority
PT
Portugal
Prior art keywords
increasing
methods
plasma exposure
sepiapterin
sepiapterin plasma
Prior art date
Application number
PT198118887T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Ptc Therapeutics Mp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc filed Critical Ptc Therapeutics Mp Inc
Publication of PT3801536T publication Critical patent/PT3801536T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PT198118887T 2018-05-30 2019-05-30 Administração de sepiapterina sem alimentos para utilização num método para aumentar a exposição plasmática a sepiapterina PT3801536T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862677943P 2018-05-30 2018-05-30
US201862771398P 2018-11-26 2018-11-26
US201962822376P 2019-03-22 2019-03-22
GC201937663 2019-05-28

Publications (1)

Publication Number Publication Date
PT3801536T true PT3801536T (pt) 2024-09-19

Family

ID=68699037

Family Applications (1)

Application Number Title Priority Date Filing Date
PT198118887T PT3801536T (pt) 2018-05-30 2019-05-30 Administração de sepiapterina sem alimentos para utilização num método para aumentar a exposição plasmática a sepiapterina

Country Status (20)

Country Link
US (3) US11617752B2 (https=)
EP (2) EP3801536B1 (https=)
JP (2) JP7502197B2 (https=)
CN (1) CN112703002A (https=)
AU (2) AU2019277382B2 (https=)
CA (1) CA3102106A1 (https=)
DK (1) DK3801536T3 (https=)
ES (1) ES2986920T3 (https=)
FI (1) FI3801536T3 (https=)
HR (1) HRP20241213T1 (https=)
HU (1) HUE068589T2 (https=)
LT (1) LT3801536T (https=)
MD (1) MD3801536T2 (https=)
MX (2) MX2020012979A (https=)
PL (1) PL3801536T3 (https=)
PT (1) PT3801536T (https=)
RS (1) RS65874B1 (https=)
SI (1) SI3801536T1 (https=)
SM (1) SMT202400430T1 (https=)
WO (1) WO2019232130A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
CN112654356A (zh) 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法
CA3165636A1 (en) * 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
US20230077104A1 (en) * 2020-02-19 2023-03-09 The United States Government As Represented By The Department Of Veteran Affairs L-sepiapterin and methods of use for treating diseases and disorders
JP2024506336A (ja) * 2021-02-09 2024-02-13 ピーティーシー セラピューティクス エムピー,インコーポレイテッド 膠芽腫の治療方法
EP4291196A1 (en) * 2021-02-09 2023-12-20 PTC Therapeutics MP, Inc. Methods for treating covid-19 with sepiapterin
CN120732846A (zh) * 2025-04-09 2025-10-03 中南大学湘雅医院 吲哚乙酸在制备预防或治疗高血压产品中的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
CA2228970A1 (en) 1995-08-18 1997-02-27 Donald W. Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
EP1696877A4 (en) * 2003-11-13 2010-06-09 Gen Hospital Corp PROCESS FOR PAIN TREATMENT
US7732599B2 (en) 2003-11-17 2010-06-08 Biomarin Pharmaceutical Inc. Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin
KR20070005550A (ko) 2003-11-17 2007-01-10 바이오마린 파머수티컬 인크. 대사 장애 치료를 위한 조성물 및 방법
CA2678125C (en) 2003-11-17 2014-10-14 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
CA2588994A1 (en) 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
US7582799B2 (en) 2005-04-28 2009-09-01 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
WO2008128049A2 (en) 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
US20110144117A1 (en) 2008-08-12 2011-06-16 Orpha Swiss Gmbh Pharmaceutical Dosage Form Containing Tetrahydrobiopterin
EP2562176B1 (en) 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
IN2014DN09053A (https=) 2012-05-07 2015-05-22 Shiratori Pharm
US10365267B2 (en) 2014-10-31 2019-07-30 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
KR102895167B1 (ko) * 2017-11-23 2025-12-04 가부시키가이샤 한도오따이 에네루기 켄큐쇼 표시 장치 및 전자 기기
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
CN112654356A (zh) * 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Also Published As

Publication number Publication date
CN112703002A (zh) 2021-04-23
EP3801536A1 (en) 2021-04-14
EP4454704A3 (en) 2025-01-01
US12329757B2 (en) 2025-06-17
MX2020012979A (es) 2021-04-29
EP3801536B1 (en) 2024-07-17
JP2024069192A (ja) 2024-05-21
ES2986920T3 (es) 2024-11-13
LT3801536T (lt) 2024-09-25
HUE068589T2 (hu) 2025-01-28
SMT202400430T1 (it) 2024-11-15
US11617752B2 (en) 2023-04-04
EP3801536A4 (en) 2022-03-23
US20230381181A1 (en) 2023-11-30
EP4454704A2 (en) 2024-10-30
SI3801536T1 (sl) 2024-12-31
MD3801536T2 (ro) 2024-11-30
PL3801536T3 (pl) 2025-02-03
HRP20241213T1 (hr) 2024-11-22
RS65874B1 (sr) 2024-09-30
US20210220363A1 (en) 2021-07-22
FI3801536T3 (fi) 2024-08-29
AU2025200814A1 (en) 2025-02-27
DK3801536T3 (da) 2024-08-19
JP7502197B2 (ja) 2024-06-18
WO2019232130A1 (en) 2019-12-05
MX2024005935A (es) 2024-06-04
AU2019277382B2 (en) 2025-01-09
JP2021525729A (ja) 2021-09-27
AU2019277382A1 (en) 2021-01-21
CA3102106A1 (en) 2019-12-05
JP7841005B2 (ja) 2026-04-06
US20260091037A1 (en) 2026-04-02

Similar Documents

Publication Publication Date Title
PT3801536T (pt) Administração de sepiapterina sem alimentos para utilização num método para aumentar a exposição plasmática a sepiapterina
IL263093B (en) Plasma-based coatings and methods for their preparation and use
IL279632A (en) Compounds and Methods for Reducing LRRK2 Expression
IL268217A (en) exposure device
GB2568748B (en) Projection apparatus
SG11201807876SA (en) Photosensitive film
GB201808433D0 (en) Process
IL281207A (en) Metrological device
IL279368A (en) Metrological device
GB201807759D0 (en) Process
ZA201903649B (en) Treatment for primary biliary cholangitis
EP3876307C0 (en) FILM PRODUCTION PROCESS
GB201809199D0 (en) Process
GB201806320D0 (en) Process
GB201806127D0 (en) Process
IL279285A (en) Industrious electrostatic core
ZA202005776B (en) Wear-levelling apparatus for cyclones
GB201811056D0 (en) Process
GB201506943D0 (en) Apparatus for fused deposition modelling
SG11202100108SA (en) Tie-coat composition
GB201813451D0 (en) Plasma apparatus
GB201819037D0 (en) Cryo-battery for tokamak
GB201810184D0 (en) Process
GB201802710D0 (en) Process
SG10201700216UA (en) Exposure apparatus